Effects of Lactobacillus acidophilus and Bifidobacterium bifidum Probiotics on the Expression of MicroRNAs 135b, 26b, 18a and 155, and Their Involving Genes in Mice Colon Cancer

Heydari, Zahra; Rahaie, Mahdi; Alizadeh, Ali Mohammad; Agah, Shahram; Khalighfard, Solmaz; Bahmani, Sahar

doi:10.1007/s12602-018-9478-8

Cited by 52 publications

(37 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison with nonallergic infants, intestinal Lactobacillus and Bifidobacterium and Lactobacillus are disappeared, and Enterobacteriaceae and Staphylococcus aureus are colonized more in some sick infants. In addition, B. bifidum has been found to have many health promoting properties, including anticancer (Heydari et al, 2018), antidiabetic (Sharma et al, 2016), anti-lipid accumulation (Wang et al, 2018), anti-inflammation (Philippe et al, 2011;Wang et al, 2016), and affect the profile of gut microbiota (Wang et al, 2019) so on. B. bifidum may have beneficial effects on CMPA infants by effecting gut microbiota.…”

mentioning

confidence: 99%

Bifidobacterium bifidumTMC3115 ameliorates milk protein allergy in by affecting gut microbiota: A randomized double‐blind control trial

2020

View full text Add to dashboard Cite

We aimed to explore the effects of Bifidobacterium bifidum TMC3115 intervention on cow's milk protein allergy (CMPA) and gut microbiota in infants. A total 256 CMPA infants were randomly and evenly assigned into an intervention group (B. bifidum) and a control group (placebo). Allergic scores, anti-inflammatory responses, and secondary outcomes were measured. Fecal specimens were collected, and the gut microbiota were analyzed by using 16S rDNA sequencing. After 6-month B. bifidum intervention, B. bifidum TMC3115 consumption reduced allergic scores, and improved anti-inflammatory responses and secondary outcomes in CMPA infants. LEfSe analysis showed Bifidobacterium, Lactobacillus, Turicibacter, Sutterella, and Parabacteroides were the most predominant phylum in the intervention group, whereas the Firmicutes (Anaerovibrio, Christensenellaceae, Oscillibacter, Bilophila, Dorea, and Roseburia) were most dominant phyla in the control group. Serum IgE or IgG2 had a strong relationship with α-diversity scores of gut microbiota. Practical applications There is a high level of prevalence of milk allergy in infants, which is difficult to be treated. Bifidobacterium bifidum TMC3115 supplement reduced allergic scores, improved anti-inflammatory responses, and reduced serum level of IgE and increased the level of IgG2 in the infants. On the contrary, B. bifidum supplement increased the genus proportion of probiotics and reduced the proportion of pathogens. The improvement of gut microbiota will be beneficial in the prevention of milk allergy. B. bifidum TMC3115 reduces milk allergy in the infants by regulating gut microbiota, and should be developed a potential way in the prevention of infant milk allergy.

show abstract

mentioning

confidence: 99%

Bifidobacterium bifidumTMC3115 ameliorates milk protein allergy in by affecting gut microbiota: A randomized double‐blind control trial

2020

View full text Add to dashboard Cite

show abstract

“…In the study of Heydari et al who used an animal colon cancer model, it was shown that the administration of Lactobacillus acidophilus DSM 13421 and Bifidobacterium bifidum at a dose 1 × 10 9 CFU/g for 5 months increased the expression of miR-26b, miR-18a, APC, PU.1 as well as PTEN while reducing the expression of miR135b, miR-155, KRAS. 48 Due to the increased expression of the tumor suppressor miRNAs and decreased level of the oncogenes after the treatment with probiotics, it was concluded that they may be considered as advantageous for colon cancer treatment. 48 Probiotics may also effectively protect the intestinal mucosa barrier in patients with colorectal cancer after surgical procedures; this was revealed in a meta-analysis of randomized, controlled trials (17 studies, n = 1242).…”

Section: Probioticsmentioning

confidence: 99%

Therapeutic methods of gut microbiota modification in colorectal cancer management – fecal microbiota transplantation, prebiotics, probiotics, and synbiotics

Kaźmierczak-Siedlecka

et al. 2020

View full text Add to dashboard Cite

The link between gut microbiota and the development of colorectal cancer has been investigated. An imbalance in the gut microbiota promotes the progress of colorectal carcinogenesis via multiple mechanisms, including inflammation, activation of carcinogens, and tumorigenic pathways as well as damaging host DNA. Several therapeutic methods are available with which to alter the composition and the activity of gut microbiota, such as administration of prebiotics, probiotics, and synbiotics; these can confer various benefits for colorectal cancer patients. Nowadays, fecal microbiota transplantation is the most modern way of modulating the gut microbiota. Even though data regarding fecal microbiota transplantation in colorectal cancer patients are still rather limited, it has been approved as a clinical method of treatment-recurrent Clostridium difficile infection, which may also occur in these patients. The major benefits of fecal microbiota transplantation include modulation of immunotherapy efficacy, amelioration of bile acid metabolism, and restoration of intestinal microbial diversity. Nonetheless, more studies are needed to assess the long-term effects of fecal microbiota transplantation. In this review, the impact of gut microbiota on the efficiency of anti-cancer therapy and colorectal cancer patients' overall survival is also discussed.

show abstract

“…e relative expression of miR-135b, miR-155, and KRAS have been reduced while the expression of miR-26b, miR-18a, APC, PU.1, and PTEN were increased in the probiotic-treated group compared to nonprobiotic group. e study suggested that the probiotic exhibited antitumor property by regulating the miRNAs and associated genes in CRC experimental mice [48].…”

mentioning

confidence: 98%

“…Heydarii et al [48] investigated the influence of supplementation of probiotics on the microRNA regulation in azoxymethane-induced CRC mice. About 5-month intervention of L. acidophilus (1 × 10 9 CFU/day) and B. bifidum (1 × 10 9 CFU/day) improved the expression pattern of miRNA-associated with cancer prevention.…”

mentioning

confidence: 99%

The Role of Probiotics in Colorectal Cancer Management

Sivamaruthi

Kesika

Chaiyasut

2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common cancerous diseases worldwide and causes leading cancer-associated deaths. Several factors are related to the incidence of CRC such as unhealthy diet and lifestyle, heredity, metabolic disorders, and genetic factors. Even though several advanced medical procedures are available for CRC treatment, the survival rates are poor with many adverse treatments associated side effects, which affects the quality of life. Probiotics are a well-known bioactive candidate for the treatment of several diseases and ill-health conditions. e recent scientific evidence suggested that probiotic supplementation protects the CRC patients from treatment-associated adverse effects. e manuscript summarizes the influence of probiotic supplementation on the health status of CRC patients and discusses the possible mechanism behind the protective effect of probiotics against CRC. e literature survey revealed that beneficial impact of probiotic supplementation depends on several factors such as strain, dosage, duration of the intervention, host physiology, and other food supplements. e probiotic intervention improves the microbiota, releases antimicrobials and anticarcinogenic agents, helps to remove carcinogens, and improves the intestinal permeability, tight junction function, and enzyme activity in CRC patients. Besides, not all probiotic strains exhibit anti-CRC activities; it is necessary to screen the potent strain for the development of a probiotic-based therapeutic agent to control or prevent the incidence of CRC.

show abstract

Effects of Lactobacillus acidophilus and Bifidobacterium bifidum Probiotics on the Expression of MicroRNAs 135b, 26b, 18a and 155, and Their Involving Genes in Mice Colon Cancer

Cited by 52 publications

References 49 publications

Bifidobacterium bifidumTMC3115 ameliorates milk protein allergy in by affecting gut microbiota: A randomized double‐blind control trial

Bifidobacterium bifidumTMC3115 ameliorates milk protein allergy in by affecting gut microbiota: A randomized double‐blind control trial

Therapeutic methods of gut microbiota modification in colorectal cancer management – fecal microbiota transplantation, prebiotics, probiotics, and synbiotics

The Role of Probiotics in Colorectal Cancer Management

Contact Info

Product

Resources

About